Generation Bio Revenue and Competitors

Claim your profile

Boston, MA USA

Location

$460.4M

Total Funding

Gaming

Industry

Estimated Revenue & Valuation

  • Generation Bio's estimated annual revenue is currently $38.4M per year.(i)
  • Generation Bio received $100.0M in venture funding in February 2018.
  • Generation Bio's estimated revenue per employee is $220,894
  • Generation Bio's total funding is $460.4M.
  • Generation Bio's current valuation is $396.7M. (January 2022)

Employee Data

  • Generation Bio has 174 Employees.(i)
  • Generation Bio grew their employee count by 19% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M35-5%N/AN/A
#2
$5.2M340%$23.9MN/A
#3
$38.4M17419%$460.4MN/A
#4
$1.9M16167%N/AN/A
#5
$7.8M4855%N/AN/A
#6
$5.7M3815%N/AN/A
#7
$102.8M44031%N/AN/A
#8
$5.7M383%N/AN/A
#9
$9.3M514%N/AN/A
#10
$5.7M3540%N/AN/A

Generation Bio is creating a revolutionary new class of genetic medicines that deliver durable, high levels of gene expression and have drug-like properties, including ability to titrate to effect and re-dose. Our unique GeneWave technology allows us to overcome the limitations of other approaches by delivering larger genes, including more sophisticated regulatory elements, and avoiding the immunogenicity which limits both the number of patients who can be treated and the ability to re-dose them over time. We are a community of creative problem-solvers and independent thinkers. We are guided by strong personal integrity, humility, and the collaborative, learning mindset required to create solutions for patients and their families. To learn more about our efforts to usher in a new generation in medicine, please visit www.generationbio.com or our Twitter feed, @lifetimegeneTX.

keywords:N/A

$460.4M

Total Funding

174

Number of Employees

$38.4M

Revenue (est)

19%

Employee Growth %

$396.7M

Valuation

N/A

Accelerator

Generation Bio News

2022-04-20 - Next Generation Bio-therapeutics Market 2022–Global ...

Data Bridge Market Research has used a versatile approach to focus attention on Demand and Sales of Next Generation Bio-therapeutics Market.

2022-04-06 - Where Does Generation Bio Co (GBIO) Stock Fall in the Biotechnology Field After It Is Higher By 2.43% This Week?

Generation Bio Co (GBIO) is around the top of the Biotechnology industry according to InvestorsObserver. GBIO received an overall rating of...

2022-03-30 - Generation Bio Co.

Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for...

2021-05-12 - GENERATION BIO CO. Generation Bio Presents Preclinical Data Demonstrating Broad Potential of Gene Therapy Platform at ASGCT and Reports First Quarter Financial Results

Durable, therapeutically relevant levels of anti-SARS-CoV-2 spike antibodies produced from the liver in a mouse model Next-generation rapid enzymatic synthesis of closed-ended DNA further increases the efficiency and scale of the manufacturing platform Potent factor VIII construct optimized by ...

2020-01-12 - Generation Bio Announces $110 Million Series C Financing

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Generation Bio, a company leading a new generation of gene therapy, announced the closing of a $110 million Series C financing. Proceeds will be used to advance the company’s two lead liver-targeted programs for hemophilia A and phenylketonuria (PKU) into IND-e ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$34.5M17418%N/A
#2
$32.1M17726%N/A
#3
$40.9M17714%N/A
#4
$53.8M17871%N/A
#5
$35.4M179N/AN/A

Generation Bio Funding

DateAmountRoundLead InvestorsReference
2018-01-09$25.0MAAtlas VentureArticle
2018-02-28$100.0MBFidelity Management & Research CompanyArticle